X-Feed Billboard (International)
The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.
GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.
/ Not for distribution to U.S. news wire services or for dissemination in the United States /
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference
VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | OTC PINK: GURFF | FRA: Q3J) (the "Company") announces that Mr. Eli Dusenbury has stepped down as Chief Financial Officer of the Company.
VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism Scientific Labs Inc. The BAR may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca).
CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $1.9 million, or ($0.32) per diluted share, on net sales of $29.5 million for the fourth quarter of fiscal year 2024 compared to a net income of $2.0 million, or $0.35 per diluted share, in the fourth quarter of the prior fiscal year.
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
ORINDA, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (OTCQX: MKZR) (“MacKenzie” or the “Company”) is pleased to announce that it has once again declared its regular quarterly dividend for the period ended September 30, 2024, in the amount of $0.125 per share, which is scheduled to be paid on October 25, 2024 to stockholders of record as of the close of business on September 30, 2024.
El costo por el uso de llamadas y extos yatos incurridos por clientes en los condados más afectados no se aplicará desde el 26 de septiembre hasta el 5 de octubre.
BOSTON, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Worlds Inc. (Worlds) (OTCQB: WDDD) announces today that it is parting ways with Jordan Freeman. Mr. Freeman had been a director of Worlds since his appointment on May 14, 2024. On August 27, 2024, Worlds announced it had closed on an agreement to license the ZOOM Platform and certain other intellectual properties. That release was deployed prematurely, prior to the execution of such agreement and closure of the same. Subsequent to the announcement, Mr. Freeman expressed his desire to resign. Accordingly, the parties have agreed to terminate further discussions and Mr. Freeman has resigned from Worlds’ board of directors.
TORONTO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Fredonia Mining Inc. (TSXV: FRED) (the “Company” or “Fredonia”) is pleased to announce the closing of its previously announced non-brokered private placement, consisting of a total of 33,333,333 units of the Company (each, a “Unit”, and collectively the “Units”), at a price of $0.03 per Unit for aggregate gross proceeds to the Company of $1,000,000 (the “Offering”). The Company did not pay any bonus, finder’s fee, commission, or agency fee in connection with the Offering.
Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market
LONDON, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW), a leading provider of quantum-safe encryption, today announced a leadership transition. Andy Leaver, a seasoned software company executive and Operating Partner from Notion Capital, has been appointed as Chief Executive Officer and a member of the Board of Directors, effective today. Co-Founder and current CEO David Williams will step down from his role as CEO and as a member of the Board of Directors. The executive transition reflects a broader transition within the company from its early development stage to a phase of revenue and operational growth.
HOUSTON, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Targa Resources Corp. (NYSE: TRGP) ("Targa" or the "Company") announced today that representatives from the Company will participate virtually from Houston, TX in investor meetings at the Wolfe Research Utilities, Midstream & Clean Energy Conference held in New York, NY on Monday, September 30, 2024.
Nashville, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) — America’s Patriotic Brand (the “Company”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-9, to be effective as of 12:00 a.m. Eastern Time on October 2, 2024.
SOMERSET, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study that shows a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 CARVYKTI® is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1 These results were presented as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65) in Rio de Janeiro, Brazil.1
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.